The Stress Hormone Was Already Elevated Before Frequent Cannabis Users Opened Their Eyes
#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating frequent cannabis users should understand that elevated baseline stress hormones may represent a pre-existing vulnerability rather than a cannabis-induced effect, which could inform more accurate risk stratification and patient counseling. This distinction matters for patients seeking to understand whether cannabis use is causally worsening their stress physiology or whether underlying stress dysregulation predates their use pattern. Recognizing this baseline difference could help clinicians tailor interventions that address the underlying stress vulnerability alongside any cannabis-related concerns.
This study examined baseline cortisol levels in frequent cannabis users, finding that elevated stress hormone concentrations were present prior to acute cannabis exposure, suggesting a pre-existing physiological state rather than an acute cannabis-induced effect. The research indicates that frequent cannabis users may have chronic hypothalamic-pituitary-adrenal axis dysregulation characterized by persistently elevated cortisol, which has implications for understanding both the motivations behind chronic use and potential long-term health consequences. The findings connect to reported associations between frequent cannabis use and reduced psychological well-being metrics including lower life satisfaction and hopefulness. For clinicians, this suggests that baseline cortisol elevation in cannabis-using patients may reflect underlying stress, anxiety, or mood disorders that warrant independent assessment and treatment rather than attributing all psychological symptoms solely to cannabis use. Patients using cannabis frequently to manage stress should be counseled that elevated baseline cortisol may indicate that their underlying condition is not adequately controlled and that alternative or adjunctive therapeutic approaches should be considered. Clinicians should measure or consider cortisol dysregulation as a potential biological marker when evaluating frequent cannabis users presenting with mood or anxiety symptoms.
💊 This finding suggesting that elevated cortisol precedes heavy cannabis use rather than resulting from it raises important questions about the temporal relationship between stress physiology and cannabis consumption patterns in clinical populations. While the cross-sectional nature of most cannabis research limits causal inference, the possibility that individuals with dysregulated stress responses may self-select into frequent use has significant implications for how we assess and counsel patients, particularly those presenting with both anxiety symptoms and cannabis use disorders. Providers should recognize that baseline physiological stress markers and psychiatric vulnerabilities may contribute to cannabis initiation and escalation, rather than viewing cannabis use solely as a driver of neuroendocrine dysfunction. However, we must remain cautious about over-interpreting findings from a single study and acknowledge that even if baseline cortisol elevation predates use, chronic cannabis consumption may still perpetuate or worsen HPA axis dysregulation through different mechanisms. In clinical practice, screening for pre-existing stress
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
